TJPC's subsidiary compound potassium hydrogen phosphate injection has passed the consistency evaluation of generic drugs

According to the Zhitong Finance APP, TJPC (600488.SH) announced that its subsidiary Tianjin Jiayao Heping Pharmaceutical Co., Ltd. (referred to as "Jiayao Heping") has received the "Drug Supplement Application Approval Notice" issued by the National Medical Products Administration for the compound potassium hydrogen phosphate injection, which approves the product to pass the consistency evaluation of generic drug quality and efficacy.

As a phosphorus supplement, the compound potassium hydrogen phosphate injection is mainly used for: (1) correcting hypophosphatemia in adult and pediatric patients when oral or enteral nutrition cannot be performed, is insufficient, or is contraindicated; (2) providing parenteral nutrition for adult and pediatric patients when oral or enteral nutrition cannot be performed, is insufficient, or is contraindicated. In July 2024, Jiayao Heping submitted a supplementary application for the consistency evaluation of the compound potassium hydrogen phosphate injection to the Drug Evaluation Center of the National Medical Products Administration, which has been accepted. So far, Jiayao Heping has invested approximately 9.21 million yuan in research and development for the compound potassium hydrogen phosphate injection project